Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular, Molecular, and Tumor Biology 34: Molecular Alterations in Genitourinary Tumors

The p110 isoform of human EGF receptor is differentially expressed in serous vs. mucinous ovarian cancer

Jessica N. McAlpine, Wenxin Zheng, Setsuko K. Chambers, Trace A. Christensen, Maritza Martel, Jill L. Reiter and Nita J. Maihle
Jessica N. McAlpine
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenxin Zheng
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Setsuko K. Chambers
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trace A. Christensen
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maritza Martel
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill L. Reiter
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita J. Maihle
Yale University School of Medicine, New Haven, CT and Tumor Biology Program, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

1803

Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in the US. The epidermal growth factor receptor (EGFR) family of tyrosine kinases plays an important role in the etiology and progression of this disease. Several soluble isoforms of the human EGFR have been described which arise from alternate transcripts. These soluble isoforms (sEGFR) contain sequences that encode only the extracellular domain of the receptor in addition to unique carboxy-terminal sequences1. One isoform, p110 sEGFR, has potential utility as a serum biomarker for ovarian cancer. We have demonstrated that p110 sEGFR is the major circulating form of EGFR in serum, where it is detected at significantly lower levels in women with EOC2. While the EGFR and its related family members have been implicated in ovarian carcinogenesis, previous studies on the expression of EGFR in human EOC have resulted in discordant observations. We predict that some of this discordance is based on the inability of investigators to distinguish between full-length EGFR and its isoforms using IHC. To date, expression of p110 sEGFR in ovarian tissues/tumors has not been studied. We have generated an antibody specific for the unique carboxy-terminal sequence of human p110 sEGFR3. Using this antibody, immunohistochemistry (IHC) was performed on normal ovarian tissue, benign tumors, tumors of low malignant potential (LMP’s), and in all major histologic subtypes of EOC. IHC staining was scored using 3 parameters: intensity(0-3+), percent distribution, and heterogeneity(0-3). We found p110 sEGFR is consistently expressed in the ovarian surface epithelium and in epithelial inclusion cysts in normal ovary. In addition, p110 sEGFR expression in serous tumors (benign cystadenomas, LMP’s, and carcinomas) is higher and more uniform in distribution than in tumors of mucinous differentiation. The expression of p110 sEGFR also is significantly higher in invasive EOC’s than in LMP’s. These results will be confirmed in a larger cohort using an ovarian tissue/tumor microarray of 404 samples, comparing expression of full-length p170 EGFR to p110 sEGFR. Given the potential utility of p110 sEGFR as a serum biomarker in EOC patients, understanding the pattern of p110 sEGFR expression in ovarian tumors, especially in relation to p170 EGFR, is a critical avenue of investigation. (Supported by the NIH CA85133). 1Reiter et al., 2001 Genomics 71:1. 2Baron et al., 2003 Cancer Epidemiol. Biomarkers Prev. 12:103. 3Christensen et al., 2002 Hybrid. Hybridomics 21:183.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The p110 isoform of human EGF receptor is differentially expressed in serous vs. mucinous ovarian cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
The p110 isoform of human EGF receptor is differentially expressed in serous vs. mucinous ovarian cancer
Jessica N. McAlpine, Wenxin Zheng, Setsuko K. Chambers, Trace A. Christensen, Maritza Martel, Jill L. Reiter and Nita J. Maihle
Cancer Res April 1 2004 (64) (7 Supplement) 414;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The p110 isoform of human EGF receptor is differentially expressed in serous vs. mucinous ovarian cancer
Jessica N. McAlpine, Wenxin Zheng, Setsuko K. Chambers, Trace A. Christensen, Maritza Martel, Jill L. Reiter and Nita J. Maihle
Cancer Res April 1 2004 (64) (7 Supplement) 414;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Altered expression and loss of heterozygosity of the LOT1 gene in cancer
  • Inhibin resistance and activin responsiveness are associated with aggressive tumorigenicity of ovarian cancer cells
  • Over-expression of death domain containing protein-p84N5 in human ovarian cancer cell lines is associated with cell proliferation
Show more Cellular, Molecular, and Tumor Biology 34: Molecular Alterations in Genitourinary Tumors
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement